hepatitis studies shyam kottilil m.d., ph.d. laboratory of immunoregulation national institute of...
TRANSCRIPT
![Page 1: Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of](https://reader035.vdocuments.us/reader035/viewer/2022062619/55162c5055034694308b5e3b/html5/thumbnails/1.jpg)
Hepatitis Studies
Shyam Kottilil M.D., Ph.D.
Laboratory of Immunoregulation
National Institute of Allergy and InfectiousDiseases
National Institutes of Health
Department of Health and Human Services
Bethesda, MD
![Page 2: Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of](https://reader035.vdocuments.us/reader035/viewer/2022062619/55162c5055034694308b5e3b/html5/thumbnails/2.jpg)
Hepatitis C and HIV coexist in the US
0
1
2
3
4
5
Num
ber a
ffect
ed (m
illio
ns)
HCV
HIV
Sulkowski MS, Mast EE, Seeff, LB et al. Hepatitis C Virus Infection as an Opportunistic Disease in Persons infected with Human Immunodeficiency Virus. Clin Infect Dis. 2000;30:577-84.
Population
All HIV+
0
20
40
60
80
100
Perc
enta
ge
IVDU90%
33%
Population
![Page 3: Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of](https://reader035.vdocuments.us/reader035/viewer/2022062619/55162c5055034694308b5e3b/html5/thumbnails/3.jpg)
Washington, D.C. Our Nation’s Capital
3%=18000 HIV+
1.8%=12000 HCV+
![Page 4: Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of](https://reader035.vdocuments.us/reader035/viewer/2022062619/55162c5055034694308b5e3b/html5/thumbnails/4.jpg)
Establishment of Hepatitis Clinics
Average Incidence Rateper 100,000 Population
0 - 25.025.1 – 50.050.1 – 75.075.1 – 100.0100.1 – 125.0
Numbers found below each ward refer to the rate of newly reportedHIV cases per 100,000 population. Rates were calculated using 2000 Census data.
For 16% of cases, ward information was not available and therefore not displayed on this map.
HCV/HIVHCVHIV/HBVHBVHIV/HCV/HBV
![Page 5: Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of](https://reader035.vdocuments.us/reader035/viewer/2022062619/55162c5055034694308b5e3b/html5/thumbnails/5.jpg)
Hepatitis Treatment Protocols-DC-PFAP
GS-7977+RBV Anti-fibrosis
Jan Mar Sept Dec Mar JuneJune Sept
HCV DAA Tx
Peg+RBV+PI (Boc) IFN and RBV FREE Tx
TLR7 PHASE 1
Anti-fibrosis
HCV-DAA
HCV-DAA
TLR7 Phase 1Natural History
Anti-fibrosis
![Page 6: Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of](https://reader035.vdocuments.us/reader035/viewer/2022062619/55162c5055034694308b5e3b/html5/thumbnails/6.jpg)
Most Effective HIV Program
Most Effective Hepatitis Program
Washington, D.C. Our Nation’s Capital